Celularity

Celularity Net Margin

The Net Profit Margin of Celularity (CELU) as of Nov 14, 2026 is -345.76 %. In the previous year, Net Profit Margin was -106.77 % — a change of 223.83% (lower).

Net Margin

-345.76 %

YoY

223.83%

Last updated:

Net Profit Margin of Celularity is 2025 -345.76 % . Net Profit Margin of Celularity was 2024 -106.77 % . It decreases by 223.83% lower compared to the previous year.

Celularity's net margin stands at -345.8%, up from -469.3% several years earlier.

The Celularity Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-0.01 USD
Jan 1, 2019
-1,001.94 USD
Jan 1, 2020
-1,458.42 USD
Jan 1, 2021
-469.27 USD
Jan 1, 2022
78.95 USD
Jan 1, 2023
-862.04 USD
Jan 1, 2024
-106.77 USD
Jan 1, 2025
-345.76 USD
The Celularity Net Margin history
YEARNet MarginYoY
-345.76 %+223.83%
-106.77 %-87.61%
-862.04 %-1,191.82%
78.95 %-116.83%
-469.27 %-67.82%
-1,458.42 %+45.56%
-1,001.94 %+16.02 M%
-0.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celularity Stock analysis

What does Celularity do? Celularity, Inc. develops off-the-shelf placental-derived allogeneic cell therapies for cancer and immune and infectious diseases. The company operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include CAR-T cells, natural killer cells, mesenchymal-like adherent stromal cells, and exosomes targeting cancer, infectious, and degenerative diseases. The company's cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy targeting B-cell malignancies. pEXO-001 is a placental-derived exosome therapy in development. The company generates revenue through the development and commercialization of its cell therapy programs. The Cell Therapy segment focuses on developing therapies for cancer, while the Degenerative Disease segment targets conditions like osteoarthritis and neurodegenerative disorders. BioBanking involves the collection and storage of placental tissue for future therapeutic use. The primary buyers of these therapies are healthcare providers and hospitals treating patients with cancer, immune disorders, and infectious diseases. Celularity's product portfolio includes CYCART-19 for B-cell malignancies, CYNK-001 for solid tumors, and pEXO-001 for regenerative medicine. The company's target market segments are patients with cancer, immune disorders, and infectious diseases. The Degenerative Disease segment specifically addresses conditions such as osteoarthritis and neurodegenerative disorders through its cell therapy programs. BioBanking supports the company's research and development by providing a source of placental-derived cells for therapeutic development. Celularity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celularity stock

Net Profit Margin of Celularity is -345.76 % in 2025.

Net Profit Margin of Celularity changed from -106.77 % to -345.76 %, representing a 223.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Celularity since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Celularity with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Celularity

All Key Metrics — Celularity